CN101405003B - 利用a2b腺苷受体拮抗剂预防和治疗肝病的方法 - Google Patents

利用a2b腺苷受体拮抗剂预防和治疗肝病的方法 Download PDF

Info

Publication number
CN101405003B
CN101405003B CN2007800095071A CN200780009507A CN101405003B CN 101405003 B CN101405003 B CN 101405003B CN 2007800095071 A CN2007800095071 A CN 2007800095071A CN 200780009507 A CN200780009507 A CN 200780009507A CN 101405003 B CN101405003 B CN 101405003B
Authority
CN
China
Prior art keywords
methyl
formula
amino
group
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800095071A
Other languages
English (en)
Chinese (zh)
Other versions
CN101405003A (zh
Inventor
曾德婉
钟鸿雁
路易斯·贝拉尔迪内利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN101405003A publication Critical patent/CN101405003A/zh
Application granted granted Critical
Publication of CN101405003B publication Critical patent/CN101405003B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2007800095071A 2006-03-17 2007-03-16 利用a2b腺苷受体拮抗剂预防和治疗肝病的方法 Active CN101405003B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78357506P 2006-03-17 2006-03-17
US60/783,575 2006-03-17
PCT/US2007/064182 WO2007109547A2 (en) 2006-03-17 2007-03-16 Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
CN101405003A CN101405003A (zh) 2009-04-08
CN101405003B true CN101405003B (zh) 2011-05-11

Family

ID=38514256

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800095071A Active CN101405003B (zh) 2006-03-17 2007-03-16 利用a2b腺苷受体拮抗剂预防和治疗肝病的方法

Country Status (14)

Country Link
US (4) US7795268B2 (enExample)
EP (1) EP1996201A2 (enExample)
JP (2) JP5250848B2 (enExample)
KR (1) KR101428113B1 (enExample)
CN (1) CN101405003B (enExample)
AU (1) AU2007227021B2 (enExample)
CA (2) CA2646333C (enExample)
IL (1) IL194158A0 (enExample)
MX (1) MX2008011828A (enExample)
NO (1) NO20083968L (enExample)
NZ (1) NZ571324A (enExample)
RU (1) RU2457842C2 (enExample)
WO (1) WO2007109547A2 (enExample)
ZA (1) ZA200807894B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
RU2357969C2 (ru) * 2003-08-25 2009-06-10 АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе
MX2007004373A (es) 2004-10-15 2007-08-08 Cv Therapeutics Inc Metodo para prevenir y tratar el remoldeo de las vias respiratorias e inflamacion pulmonar utilizando antagonistas de receptor adenosina a2b.
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
EP2301937A1 (en) * 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrugs of A2b adenosine receptor antagonists
WO2007109547A2 (en) 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
CN101479290A (zh) * 2006-06-27 2009-07-08 比奥维特罗姆上市公司 新的2′,3′-亚甲基缩醛腺苷前药用作腺苷受体激动剂的前药
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US20090208550A1 (en) * 2007-10-26 2009-08-20 Cronstein Bruce N Methods and compositions for treating hepatic diseases
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
CA2718983C (en) 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
EP2405917B1 (en) 2009-03-13 2014-04-23 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
CN103261200B (zh) 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
US20140142113A1 (en) * 2012-11-09 2014-05-22 Michael W. Burnet Method of treating inflammatory diseases using adenosine 2b receptor antagonists
WO2016057454A1 (en) 2014-10-06 2016-04-14 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
WO2016129760A1 (ko) * 2015-02-13 2016-08-18 한국과학기술원 Tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
KR101666605B1 (ko) 2015-02-13 2016-10-18 한국과학기술원 TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
EP3368064B1 (en) 2015-10-29 2021-05-19 CLS Therapeutics Limited Use of dnase to improve safety and efficacy of anti-cancer chemotherapy
KR102852334B1 (ko) 2016-02-10 2025-09-01 웨이크 포리스트 유니버시티 헬스 사이언시즈 간 섬유화의 모델 시스템 및 그의 제조 및 사용 방법
KR101709307B1 (ko) * 2016-10-31 2017-02-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물
EP3634417B1 (en) * 2017-05-17 2023-07-12 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
EP3675856A4 (en) 2017-08-31 2021-04-14 Corvus Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR MODULATING THE A2B ADENOSINE RECEPTOR AND A2A ADENOSINE RECEPTOR
CN112218867B (zh) 2018-03-05 2023-11-21 泰昂治疗公司 腺苷受体拮抗剂及其用途
GB201804922D0 (en) 2018-03-27 2018-05-09 Ucl Business Plc Traatment
JP7394831B2 (ja) * 2018-07-27 2023-12-08 アーカス バイオサイエンシズ インコーポレイティド ピリドンａ２ｒアンタゴニスト
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042298A1 (en) * 2000-11-21 2002-05-30 Novartis Ag Aminothiazoles and their use as adenosine receptor antagonists
US20040176399A1 (en) * 2001-11-09 2004-09-09 Elfatih Elzein A2B adenosine receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532816A (en) 2001-11-09 2005-11-25 Cv Therapeutics Inc A2B adenosine receptor antagonists
ES2208063B1 (es) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
US7064204B2 (en) * 2002-05-30 2006-06-20 King Pharmacueticals Reserch And Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
WO2004086052A2 (en) 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
GB0401336D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP2301937A1 (en) 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrugs of A2b adenosine receptor antagonists
WO2007109547A2 (en) 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042298A1 (en) * 2000-11-21 2002-05-30 Novartis Ag Aminothiazoles and their use as adenosine receptor antagonists
US20040176399A1 (en) * 2001-11-09 2004-09-09 Elfatih Elzein A2B adenosine receptor antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
.2003,第4卷(第4期),p421-429,P426第2栏第2段-P427第1栏第1段. *
CURRENT OPINION IN INVESTIGATIONAL DRUGS&gt *
hongyang zhong.et al..Synergy between A2B Adenosine Receptors and Hypoxia in Activating human lung fibroblasts.&lt *
hongyang zhong.et al..Synergy between A2B Adenosine Receptors and Hypoxia in Activating human lung fibroblasts.<CURRENT OPINION IN INVESTIGATIONAL DRUGS>.2003,第4卷(第4期),p421-429,P426第2栏第2段-P427第1栏第1段.

Also Published As

Publication number Publication date
NO20083968L (no) 2008-12-15
JP5250848B2 (ja) 2013-07-31
JP2009530413A (ja) 2009-08-27
CA2646333A1 (en) 2007-09-27
RU2008137279A (ru) 2010-03-27
EP1996201A2 (en) 2008-12-03
CA2849661A1 (en) 2007-09-27
US8609671B2 (en) 2013-12-17
AU2007227021B2 (en) 2012-12-20
IL194158A0 (en) 2009-08-03
US20140243358A1 (en) 2014-08-28
WO2007109547A2 (en) 2007-09-27
US8188099B2 (en) 2012-05-29
CN101405003A (zh) 2009-04-08
NZ571324A (en) 2011-07-29
US20120220608A1 (en) 2012-08-30
CA2646333C (en) 2014-06-17
US7795268B2 (en) 2010-09-14
AU2007227021A1 (en) 2007-09-27
JP2013049719A (ja) 2013-03-14
US20110184002A1 (en) 2011-07-28
RU2457842C2 (ru) 2012-08-10
MX2008011828A (es) 2008-09-29
ZA200807894B (en) 2009-05-27
WO2007109547A3 (en) 2007-11-29
KR20080107416A (ko) 2008-12-10
US20070219221A1 (en) 2007-09-20
KR101428113B1 (ko) 2014-08-07

Similar Documents

Publication Publication Date Title
CN101405003B (zh) 利用a2b腺苷受体拮抗剂预防和治疗肝病的方法
US8466129B2 (en) Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
US7521554B2 (en) A2B adenosine receptor antagonists
US20070208040A1 (en) A2a adenosine receptor antagonists
US7317017B2 (en) A2B adenosine receptor antagonists
CN101043889B (zh) A2b腺苷受体拮抗剂在制备促使伤口愈合的药物中的应用
AU2012261721A1 (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
AU2011202523B2 (en) A2B adenosine receptor antagonists
HK1156213A (en) Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: GILEAD PALO ALTO CO., LTD.

Free format text: FORMER OWNER: CV PHARMACEUTICAL CO., LTD.

Effective date: 20100519

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20100519

Address after: American California

Applicant after: Cv Therapeutics Inc.

Address before: American California

Applicant before: CV Therapeutics Inc.

C14 Grant of patent or utility model
GR01 Patent grant